Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study-Reference-Cited by-同舟云学术

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

Published:2015-07-28 Issue:4 Volume:17 Page:255-268
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Achhra AC¹,Mocroft A²,Reiss P³,Sabin C²,Ryom L⁴,de Wit S⁵,Smith CJ²,d'Arminio Monforte A⁶,Phillips A²,Weber R⁷,Lundgren J⁸,Law MG¹,

Affiliation:

1. Kirby Institute; UNSW Australia; Sydney NSW Australia

2. Research Department of Infection & Population Health; University College London; London UK

3. Division of Infectious Diseases and Department of Global Health; University of Amsterdam; Amsterdam The Netherlands

4. University of Copenhagen; Copenhagen Denmark

5. Infectious Diseases Department; Saint-Pierre University Hospital; Brussels Belgium

6. University of Milan Clinic of Infectious Diseases; Milan Italy

7. University Hospital in Zurich; Zurich Switzerland

8. Rigshospitalet & University of Copenhagen; Copenhagen Denmark

Funder

Highly Active Antiretroviral Therapy Oversight Committee (HAART-OC)

Health Insurance Fund Council

Agence Nationale de Recherches sur le Sida et les Hepatites Virales

Asia Pacific HIV Observational Database

National Institute of Allergy and Infectious Diseases

Merck Sharp & Dohme

Gilead Sciences

Bristol-Myers Squibb Foundation

Boehringer Ingelheim

Roche

Pfizer

GlaxoSmithKline

Janssen Pharmaceuticals

Department of Health and Ageing, Australian Government

Fondo de Investigación Sanitaria

Fundación para la Investigación y la Prevención del SIDA en Espanã

BIOMED 1

BIOMED 2

European Commission

AbbVie

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference17 articles.

1. HIV infection and obesity: where did all the wasting go?;Tate;Antivir Ther,2012

2. High risk of obesity and weight gain for HIV-infected uninsured minorities;Taylor;J Acquir Immune Defic Syndr,2014

3. HIV infection and obesity: a review of the evidence;Keithley;J Assoc Nurses AIDS Care,2009

4. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV Cohort Study;Hasse;Open Forum Infect Dis,2014

5. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons;Lakey;AIDS Res Hum Retroviruses,2013

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dolutegravir-based Treatment in HIV-infected Diabetics Requires Close Cardiovascular Monitoring: A Point of Concern;Journal of Clinical Infectious Disease Society;2024-07

2. Exercise to Prevent Accelerated Vascular Aging in People Living With HIV;Circulation Research;2024-05-24

3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts;The Lancet HIV;2024-05

4. Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy;Antioxidants;2024-04-26

5. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda;AIDS Research and Therapy;2024-04-18